Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CTSO
CTSO logo

CTSO Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Cytosorbents Corp (CTSO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
0.410
1 Day change
-5.70%
52 Week Range
1.390
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Cytosorbents Corp (CTSO) is not a good buy for a beginner investor with a long-term strategy at the moment. The stock is currently in a bearish trend with no significant positive catalysts or trading signals. Additionally, the lack of financial data, recent news, and insider or hedge fund activity further reduces confidence in this investment. It is better to wait for clearer signs of recovery or positive momentum before considering this stock.

Technical Analysis

The technical indicators suggest a bearish trend. The moving averages are aligned in a bearish order (SMA_200 > SMA_20 > SMA_5), and the RSI is neutral at 45.946. The MACD histogram is slightly positive at 0.00712 but contracting, indicating weak momentum. Key support levels are at 0.38 and 0.325, with resistance at 0.47 and 0.56.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
10
Buy
2

Positive Catalysts

  • NULL identified. No recent news, insider activity, or hedge fund interest. No AI Stock Picker or SwingMax signals.

Neutral/Negative Catalysts

  • The stock experienced a significant regular market decline of -8.11% and a pre-market drop of -3.77%. The bearish moving averages and lack of trading activity from insiders or hedge funds further highlight negative sentiment.

Financial Performance

No financial data available for analysis. Latest quarter season could not be assessed due to missing information.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes available for evaluation.

Wall Street analysts forecast CTSO stock price to rise
1 Analyst Rating
Wall Street analysts forecast CTSO stock price to rise
0 Buy
1 Hold
0 Sell
Hold
Current: 0.438
sliders
Low
0.75
Averages
0.75
High
0.75
Current: 0.438
sliders
Low
0.75
Averages
0.75
High
0.75
H.C. Wainwright
Sean Lee
Neutral
downgrade
$1
AI Analysis
2025-11-14
Reason
H.C. Wainwright
Sean Lee
Price Target
$1
AI Analysis
2025-11-14
downgrade
Neutral
Reason
H.C. Wainwright analyst Sean Lee lowered the firm's price target on CytoSorbents to 75c from $1 and keeps a Neutral rating on the shares. The firm reduced estimates to reflect to the "continued drag" on the company's Germany revenues.

People Also Watch